Literature DB >> 22795728

Polymeric nanoparticles containing taxanes enhance chemoradiotherapeutic efficacy in non-small cell lung cancer.

Joohee Jung1, Sung-Jin Park, Hye Kyung Chung, Hye-Won Kang, Sa-Won Lee, Min Hyo Seo, Heon Joo Park, Si Yeol Song, Seong-Yun Jeong, Eun Kyung Choi.   

Abstract

PURPOSE: To reduce the side effects and improve the efficacy of chemoradiation therapy, taxanes were incorporated into polymeric nanoparticles (PNP), and their synergic effect on radiation therapy in non-small cell lung cancer was evaluated. METHODS AND MATERIALS: The properties of PNP-taxanes were characterized by transmission electron microscopy and dynamic light scattering. The chemoradiotherapeutic efficacy of PNP-taxanes was determined by clonogenic assay, cellular morphology, and flow cytometry in A549 cells. In mice bearing A549-derived tumors, the tumor growth delay was examined after the treatment of PNP-taxanes and/or ionizing radiation (IR).
RESULTS: The PNP-taxanes were found to be approximately 45 nm in average diameter and to have high solubility in water. They showed the properties of active internalization into cells and preserved the anticancer effect of free taxanes. The survival fraction of A549 cells by clonogenic assay was significantly reduced in the group receiving combined treatment of PNP-taxanes and IR. In addition, in vivo radiotherapeutic efficacy was markedly enhanced by the intravenous injection of PNP-taxanes into the xenograft mice.
CONCLUSIONS: We have demonstrated the feasibility of PNP-taxanes to enhance the efficacy of chemoradiation therapy. These results suggest PNP-taxanes can hold an invaluable and promising position in treating human cancers as a novel and effective chemoradiation therapy agent.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22795728     DOI: 10.1016/j.ijrobp.2012.02.030

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  22 in total

Review 1.  Nanotechnology in radiation oncology.

Authors:  Andrew Z Wang; Joel E Tepper
Journal:  J Clin Oncol       Date:  2014-08-11       Impact factor: 44.544

2.  Improving chemoradiotherapy with nanoparticle therapeutics.

Authors:  Michael Joseph Eblan; Andrew Zhuang Wang
Journal:  Transl Cancer Res       Date:  2013-08-01       Impact factor: 1.241

3.  Effect of particle size on the biodistribution, toxicity, and efficacy of drug-loaded polymeric nanoparticles in chemoradiotherapy.

Authors:  Joseph M Caster; Stephanie K Yu; Artish N Patel; Nicole J Newman; Zachary J Lee; Samuel B Warner; Kyle T Wagner; Kyle C Roche; Xi Tian; Yuanzeng Min; Andrew Z Wang
Journal:  Nanomedicine       Date:  2017-03-11       Impact factor: 5.307

Review 4.  Nanomedicine in chemoradiation.

Authors:  Seth M Miller; Andrew Z Wang
Journal:  Ther Deliv       Date:  2013-02

Review 5.  Current role of nanoparticles in the treatment of lung cancer.

Authors:  Eliseo Carrasco-Esteban; José Antonio Domínguez-Rullán; Patricia Barrionuevo-Castillo; Lira Pelari-Mici; Olwen Leaman; Sara Sastre-Gallego; Fernando López-Campos
Journal:  J Clin Transl Res       Date:  2021-03-16

6.  In vivo synergistic anti-tumor effect of paclitaxel nanoparticles combined with radiotherapy on human cervical carcinoma.

Authors:  YanXin Yu; Shan Xu; Hong You; YinJie Zhang; Bo Yang; XiaoYang Sun; LingLin Yang; Yue Chen; ShaoZhi Fu; JingBo Wu
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

7.  Human tumor xenograft models for preclinical assessment of anticancer drug development.

Authors:  Joohee Jung
Journal:  Toxicol Res       Date:  2014-03

8.  Apoptosis-Inducing Activity of Marine Sponge Haliclona sp. Extracts Collected from Kosrae in Nonsmall Cell Lung Cancer A549 Cells.

Authors:  Woori Bae; Hyun Kyung Lim; Kyoung Mee Kim; Hyosun Cho; Sun Yi Lee; Choon-Sik Jeong; Hyi-Seung Lee; Joohee Jung
Journal:  Evid Based Complement Alternat Med       Date:  2015-07-06       Impact factor: 2.629

9.  Nanoparticulated docetaxel exerts enhanced anticancer efficacy and overcomes existing limitations of traditional drugs.

Authors:  Jinhyang Choi; Eunjung Ko; Hye-Kyung Chung; Jae Hee Lee; Eun Jin Ju; Hyun Kyung Lim; Intae Park; Kab-Sig Kim; Joo-Hwan Lee; Woo-Chan Son; Jung Shin Lee; Joohee Jung; Seong-Yun Jeong; Si Yeol Song; Eun Kyung Choi
Journal:  Int J Nanomedicine       Date:  2015-09-29

10.  Preclinical evaluation of Genexol-PM, a nanoparticle formulation of paclitaxel, as a novel radiosensitizer for the treatment of non-small cell lung cancer.

Authors:  Michael E Werner; Natalie D Cummings; Manish Sethi; Edina C Wang; Rohit Sukumar; Dominic T Moore; Andrew Z Wang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-07-01       Impact factor: 7.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.